TEST:

MIRAM® kit

"Swedish cancer detection company Elypta today announces the publication of groundbreaking research conducted at Chalmers University of Technology by Elypta founders Prof. Jens Nielsen and Dr. Francesco Gatto, showcasing the multi-cancer early detection (MCED) potential of glycosaminoglycans as biomarkers of tumor metabolism...Researchers developed a test based on the measurement of free glycosaminoglycan profiles in plasma and urine using Elypta’s MIRAM kit and samples from 979 participants diagnosed with 14 different cancer types, including types difficult to detect with other methods such as brain tumors and kidney cancer, and healthy subjects."